Prolactinomas in Women: Current Therapies

  1. ALAN G. ROBINSON, M.D.; and
  2. PAUL B. NELSON, M.D.
  1. University of Pittsburgh;
    Pittsburgh, Pennsylvania

    Excerpt

    Since prolactin was shown by Kleinberg and Frantz (1) to be a hormone separate from human growth hormone and since the development of radioimmunoassays for prolactin (2), the diagnosis of hyperprolactinemia as a cause of galactorrhea and amenorrhea has become common. Among unscreened women with amenorrhea, 15% to 25% may have elevated levels of prolactin; if one preselects for galactorrhea, the incidence is even higher (3).

    Normally prolactin is under chronic suppression by dopamine, released from the hypothalamus. Prolactin secretion can be inhibited by pharmacologic agents that mimic the effect of dopamine (levodopa, bromocriptine, pergolide mesylate), and stimulated by direct

    Article and Author Information

    • Grant support: by NIH grants AM16166, NS17138, and Clinical Research Unit Grant RR-0056.

    « Previous | Next Article »Table of Contents